Last reviewed · How we verify
TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer
This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.
Details
| Lead sponsor | PharmAbcine |
|---|---|
| Phase | PHASE1 |
| Status | UNKNOWN |
| Enrolment | 11 |
| Start date | Thu Jan 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Oct 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Triple Negative Breast Cancer
Interventions
- TTAC-0001 and pembrolizumab combination
Countries
Australia